Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that members of the management team will participate at the following upcoming investor conferences:
To access the live audio webcast of the presentations, please visit the “Events & Presentations” section of the Arcus website at https://investors.arcusbio.com/investors/events-and-presentations. A replay of the webcast will be available for 30 days following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small molecule inhibitor of CD73, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101006030/en/
Arcus Biosciences
Jennifer Jarrett
(510) 694-6261
jjarrett@arcusbio.com
Or
Nicole
Arndt
(510) 284-4728
narndt@arcusbio.com